COVID-19 trials registries data warehouse

 Return to trial list

Trial - CTRI/2021/03/031721


Column Value
Trial registration number CTRI/2021/03/031721
Full text link
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

First author
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Dr Bharti Wadhwa

Contact
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

drbhartitaneja@gmail.com

Registration date
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2021-03-04

Recruitment status
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not recruiting

Study design
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

RCT

Allocation
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Randomized

Design
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Parallel

Masking
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Blind label

Center
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

single-center

Study aim
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Treatment

Inclusion criteria
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Confirmed COVID-19 by RT PCR test <br/ >Hospitalized Non ventilated patients with oxygen by mask or nasal prongs (WHO <br/ >Ordinal Scale 4: Appendix 1) <br/ >SpO2 < 94% on room air but maintaining SpO2 of >94% on VenturiMask / Non <br/ >rebreathing mask <br/ >

Exclusion criteria
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Participation in another clinical trial of an investigational medicinal product <br/ > Known hypersensitivity to the IMP <br/ >Significant electrolyte disturbance (Hyperkalemia: K+ >5.0 mmol/L) <br/ >Patient currently receiving potassium sparing diuretics that cannot be reasonably <br/ >withheld <br/ >â?¢ Acute renal insufficiency <br/ >â?¢ In the Investigatorâ??s opinion, patient is unwilling or unable to comply with drug <br/ >administration plan, laboratory tests or other study procedures. <br/ >â?¢ Pregnant or lactating patient <br/ >â?¢ Patients on the following drugs : ACE inhibitors, Amiloride, Hydrocortisone, <br/ >Prednisolone, Methylprednisolone, Triamterene

Number of arms
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2

Funding
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

None

Inclusion age min
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

18

Inclusion age max
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

85

Countries
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

India

Type of patients
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Moderate/severe disease at enrollment

Severity scale
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

4: Moderate/severe disease at enrollment

Total sample size
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

120

primary outcome
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

1.The time to recover; defined as the first day; during the 28 days after enrollment; on which a patient met the criteria for category 1;2; 0r 3 WHO ordinal scale. <br/ >2.To determine the effect of the medication on Von Willebrand Factor; Angiotensin II; aldosterone and D-Dimer Levels.Timepoint: Baseline <br/ >Day 1 <br/ >Day 4 <br/ >Day 7

Notes
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

| Declared number of arm (5.0) differs from found arms (6.0)

Phase
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not reported

Arms
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

[{"arm_notes": "50mg on day 1 followed by 25mg till day 21", "treatment_id": 1228, "treatment_name": "Spironolactone", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "6mg only for ten days", "treatment_id": 400, "treatment_name": "Dexamethasone", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}]